Category distinction
Methylene blue is not just another nootropic supplement
Methylene blue appears in online focus and longevity marketing, but it is still a medication-related compound with specific interaction and G6PD safety questions. FDA labeling for intravenous methylene blue products warns about serious or fatal serotonin syndrome when combined with serotonergic psychiatric medicines. Low-dose oral use for focus or longevity should not erase that medication-review burden.
- Ask whether the product is prescribed, compounded, or sold as a chemical or supplement, and who reviews eligibility before use.
- Review SSRIs, SNRIs, MAOIs, opioids, dextromethorphan, migraine medicines, stimulants, linezolid, lithium, St. John’s wort, tryptophan, 5-HTP, and multi-ingredient nootropic blends.
- Do not stop psychiatric, pain, migraine, sleep, or other prescribed medicines just to qualify for methylene blue; medication changes belong with the prescribing clinician.